Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Consensus Target Price from Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $4.94.

Several research firms recently issued reports on CARM. Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a research note on Monday, January 13th. Finally, Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Carisma Therapeutics Stock Up 1.5 %

Shares of Carisma Therapeutics stock opened at $0.46 on Friday. The firm has a market cap of $19.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.56. The stock has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $0.84. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.77. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last posted its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. On average, equities research analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carisma Therapeutics

Several large investors have recently made changes to their positions in the business. Wexford Capital LP increased its holdings in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Carisma Therapeutics during the second quarter worth about $40,000. Finally, Barclays PLC increased its stake in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.